Our Partnership
Key Structures
Topics
Results & Data
Impact Stories
-
23 March 2023“But I Can’t Just Give Up.” In the Shadow of War, Yulia Continues to Support People with TB in Ukraine
-
21 March 2023Tools to Turbocharge the Fight Against Tuberculosis
-
07 March 2023These Women Are Fighting Disease and Preparing for Future Health Threats
-
27 February 2023Genome Lab Technology Transforms Indonesia’s Response to Health Threats
News Releases
-
14 March 2023
Global Fund and Unitaid Welcome WHO Recommendation for Insecticide-treated Nets …
-
09 March 2023
Global Fund, USAID and Stop TB Partnership's New Collaboration With Molbio Diagn…
-
21 February 2023
Global Fund Announces Additional Emergency Funding in Ukraine After One Year of …
-
14 February 2023
Global Fund Provides US$867 Million in Additional Funding for Pandemic Preparedn…
Opinion
-
24 March 2023
Fighting Tuberculosis Will Protect Us From the Next Global Health Threat
-
20 March 2023
Tuberculosis: The Unseen Pandemic
-
01 March 2023
In Côte d’Ivoire, Sex Workers Team Up With Police to Fight Stigma and HIV
-
16 December 2022
The Criminalization of Sex Work Not Only Violates Human Rights – It Adds to HIV …
Updates
Featured
Opportunity for Evaluation of Pharmaceutical Products
13 February 2023
The Global Fund invites manufacturers of pharmaceutical products to submit an Expression of Interest (EoI) to have their products evaluated by the Expert Review Panel for pharmaceutical products (ERP).
Detailed information about the review process and submission requirements can be found on the Expert Review Panel page.
The deadline for the Submission is the 7th April 2023.
Invitation to Manufacturers to Submit an Expression of Interest for Product Evaluation by the Global Fund Expert Review Panel for Pharmaceutical Products
download in English
The Global Fund uses cookies for anonymized statistics on website use and content performance to help us improve and adapt the website. To consent to the use of cookies, please click “Accept”. To learn more about your rights and options, please read our Privacy Statement.